CAM 2028

Drug Profile

CAM 2028

Alternative Names: Benzydamine CR; CAM2028; Episil; episil; episil® oral liquid; SP-03 - Camurus

Latest Information Update: 17 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Camurus
  • Developer Camurus; Meiji Seika Pharma; Solasia Pharma; Takeda Pharmaceuticals International GmbH
  • Class Analgesics; Anti-inflammatories; Antibacterials
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Stomatitis

Most Recent Events

  • 16 May 2018 Launched for Stomatitis in Japan (Transmucosal)
  • 07 Jul 2017 Registered for Stomatitis in Japan (Transmucosal)
  • 09 Mar 2017 CAM 2028 licensed to Ethypharm in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top